Chimeric immunoreceptor useful in treating human cancers
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.
57 Citations
6 Claims
- 1. A chimeric immunoreceptor comprising SEQ ID NO:
-
2. A chimeric immunoreceptor encoded by a nucleic acid sequence comprising SEQ ID NO:
- 19 or SEQ ID NO;
23.
- 19 or SEQ ID NO;
-
4. A vector which comprises a nucleic acid comprising SEQ ID NO:
- 19 or SEQ ID NO;
23.
- 19 or SEQ ID NO;
-
5. The vector which consists essentially of SEQ ID NO:
- 19.
-
6. The vector which consists essentially of SEQ ID NO:
- 23.
Specification